# EMPEROR-Reduced

Study · id `cardio:emperor-reduced` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Empagliflozin outcome trial in heart failure with reduced ejection fraction

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A large trial in adults with heart failure and a reduced ejection fraction (40% or less) who were already taking recommended treatment. About half were given empagliflozin 10 mg once a day and half a placebo. Over a median of 16 months, fewer people on empagliflozin died from cardiovascular causes or were admitted to hospital for worsening heart failure. The authors report the effect was consistent in people with and without diabetes.

## Technical summary

Boehringer Ingelheim-sponsored (Eli Lilly and Company is a registry collaborator), randomized, double-blind, placebo-controlled phase 3 trial (NCT03057977) of 3730 patients with NYHA class II to IV heart failure and an ejection fraction of 40% or less. Primary outcome: cardiovascular death or hospitalization for worsening heart failure, hazard ratio 0.75 (95% CI 0.65 to 0.86) over a median of 16 months, from the PubMed abstract. The registry condition field says only heart failure; the registry title names reduced ejection fraction. The full text was not read. Funding is stated in the abstract as Boehringer Ingelheim and Eli Lilly.

## Key facts

- Design: Randomized, parallel-group, double-blind, placebo-controlled phase 3 trial of empagliflozin 10 mg once daily added to recommended therapy. The abstract calls it double-blind and the registry records masking as double.
- Phase: Phase 3
- Enrolled: 3730 patients (randomized count; Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, snapshot `cardio:pubmed-32865377-2026-10-14`, retrieved 2026-10-14)
- Started: 2017-03-06 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced), snapshot `cardio:ctgov-nct03057977-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2020-05-01 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced), snapshot `cardio:ctgov-nct03057977-2026-10-14`, retrieved 2026-10-14)
- Completion: 2020-05-28 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced), snapshot `cardio:ctgov-nct03057977-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2021-05-18 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced), snapshot `cardio:ctgov-nct03057977-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; China; Czechia; France; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; South Korea; Spain; United Kingdom (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced), snapshot `cardio:ctgov-nct03057977-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct03057977-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Tests this medicine: Empagliflozin (`cardio:empagliflozin`)
- Studies people with this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Lead sponsor on the registry record: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Collaborator on the registry record: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 5706b5e60f4fc3bd3b3464a14b037c3eea5f43ec119b9bf9322c92140f5421fc
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14